1 June 2022 in Science Translational Medicine
Gepotidacin is a first-in-class triazaacenaphthylene antibacterial agent that selectively inhibits bacterial DNA gyrase and topoisomerase IV through a unique binding mode and has the potential to treat a number of bacterial diseases. Development of this new agent to treat pneumonic plague caused by Yersinia pestis depends on the U.S. Food and Drug Administration Animal Rule testing pathway, as testing in humans is not feasible. Here, preclinical studies were conducted in the African green monkey (AGM) inhalational model of pneumonic plague to test the efficacy of gepotidacin. AGMs infected with Y. pestis were dosed intravenously with gepotidacin (48, 36, or 28 milligrams/kilogram per day) for 10 days to provide a plasma concentration that would support a rationale for a 1000 mg twice or thrice daily intravenous dose in humans or saline as a control. The primary end point was AGM survival with predefined euthanasia criteria. Secondary end points included survival duration and bacterial clearance. Gepotidacin showed activity in vitro against diverse Y. pestis isolates including antibiotic-resistant strains. All control animals in the inhalational plague studies succumbed to plague and were blood culture and organ culture positive for Y. pestis . Gepotidacin provided a 75 to 100% survival benefit with all dose regimens. All surviving animals were blood culture and organ culture negative for Y. pestis . Our randomized, controlled efficacy trials in the AGM pneumonic plague nonhuman primate model together with the in vitro Y. pestis susceptibility data support the use of gepotidacin as a treatment for pneumonic plague caused by Y. pestis .
1 October 2021 in Journal of Exotic Pet Medicine
RERosita Semenza Esposito
+2
Ingestion of toxic substances is a common event in companion animals and livestock, especially in waterfowl. Oleander (Nerium oleander) toxicosis is rarely reported in avian species, with symptoms including cardiac, neurological and gastrointestinal manifestations. A 6-month-old domestic goose (Anser anser domesticus) was presented for depression, anorexia, permanent sternal recumbency, weakness and incoordination, and the owners witnessed the ingestion of oleander leaves. Despite the absence of evident cardiac symptoms, biochemical hematological findings showed significant increase of CPK, AST, LDH, and troponin I. Therapy was set with intravenous (IV) fluid administration, antibiotic and anti-inflammatory, oral activated charcoal, and IV lipid emulsion at 15 mL/kg/h. Clinical improvement was achieved after 2 hours. The patient was discharged 3 days after admission, with complete recovery and return to normal biochemical values 10 days after initial presentation. The present work describes a suspected case of spontaneous oleander poisoning in a domestic goose, with the first use of troponin I to diagnose cardiac injury in this species, and the first report of IV lipid emulsion to successfully treat this kind of toxicosis in veterinary practice.